Author Correction: Serum GFAP as a Biomarker for Disease Severity in Multiple Sclerosis

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-43990-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Correction To: Gait Variability as Digital Biomarker of Disease Severity in Huntington’s Disease

Journal of Neurology
Neurology
2020English

Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity

Journal of Molecular Neuroscience
MedicineMolecular NeuroscienceCellular
2015English

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis

Frontiers in Neurology
Neurology
2019English

Serum Osteoprotegerin as a Biomarker for Vascular Disease

American Journal of Cardiology
Cardiovascular MedicineCardiology
2007English

Metabolomic Signatures Associated With Disease Severity in Multiple Sclerosis

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2017English

GFAP Expression as an Indicator of Disease Severity in Mouse Models of Alexander Disease

ASN Neuro
NeuroscienceNeurology
2013English

Serum Ferritin Is a Candidate Biomarker of Disease Aggravation in Amyotrophic Lateral Sclerosis

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2018English

Gait Variability as Digital Biomarker of Disease Severity in Huntington’s Disease

Journal of Neurology
Neurology
2020English

Evaluating Optic Nerve Diameter as a Possible Biomarker for Disability in Patients With Multiple Sclerosis

Neuropsychiatric Disease and Treatment
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy